日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Tertiary Patents on Drugs Approved by the FDA

FDA批准药物的第三级专利

Teng, Theodore W; Tu, S Sean; Mooney, Helen; Bendicksen, Liam; Gabriele, Sarah M E; Wouters, Olivier J; Feldman, William B

Microcephaly-associated protein WDR62 supports purine metabolism by interacting with co-chaperone BAG2.

与小头畸形相关的蛋白质 WDR62 通过与辅助伴侣 BAG2 相互作用来支持嘌呤代谢。

Morris Matthew J, Yeap Yvonne Y, Edwards Jonathon R, Chen Chi, Paolino Annalisa, Furness Sebastian G B, Millard S Sean, Pagan Julia K, Fenlon Laura R, Ng Dominic C H

WDR62 is required for proper proliferation and early differentiation of skeletal myoblasts

WDR62是骨骼肌成肌细胞正常增殖和早期分化所必需的。

Ho, Uda Y; Shohayeb, Belal; Kamei, Hinako; Morris, Matthew J; Yeap, Yvonne Y; Richards, Dominic; Reichelt, Melissa E; Thomas, Walter G; Noakes, Peter G; Millard, S Sean; Ng, Dominic C H

Revenue, Patents, and New Generic Competition for Prescription Drugs in the USA

美国处方药的收入、专利和新仿制药竞争

Tu, S Sean; Kesselheim, Aaron S; Ross, Joseph S; Gupta, Ravi

Prescription Drug Method-of-Use Patent Protection, 1991-2018

处方药使用方法专利保护,1991-2018 年

Bloomfield, Doni; Teng, Theodore W; Kesselheim, Aaron S; Tu, S Sean

Estimating Costs of Market Exclusivity Extensions For 4 Top-Selling Prescription Drugs in the US

估算美国四种最畅销处方药市场独占权延期的成本

Hong, Dongzhe; Tu, S Sean; Beall, Reed F; Russo, Massimiliano; Rome, Benjamin N; Kesselheim, Aaron S; Sarpatwari, Ameet

Accelerating biosimilar market access: the case for allowing earlier standing

加快生物类似药市场准入:允许更早上市的理由

Tu, S Sean; Goode, Rachel; Turner, Matthew; Van de Wiele, Victor

Recent changes in discretionary denials of drug patent challenges

近期在药品专利挑战的自由裁量权驳回方面发生了变化

Tu, S Sean; Rai, Arti; Kesselheim, Aaron S

Extent of Drug Patents With Terminal Disclaimers and Obviousness-Type Double Patenting Rejections

药物专利中存在终止声明和显而易见性重复专利驳回的情况

Tu, S Sean; Kesselheim, Aaron S; Chao, Bernard

Biologic Patent Thickets and Terminal Disclaimers

生物制剂专利丛林和最终免责声明

Tu, S Sean; Goode, Rachel; Feldman, William B